DS
ATOS icon

David Shaw’s Atossa Therapeutics ATOS Stock Holding History

David Shaw’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,435
Closed -$273K – 4245
2023
Q2 		$273K Sell
14,435
-40,456
-74% -$491K ﹤0.01% 3638
2023
Q1 		$597K Sell
54,891
-43,384
-44% -$484K ﹤0.01% 3466
2022
Q4 		$779K Sell
98,275
-19,547
-17% -$224K ﹤0.01% 3608
2022
Q3 		$1.47M Sell
117,822
-34,154
-22% -$496K ﹤0.01% 3279
2022
Q2 		$2.48M Sell
151,976
-105,566
-41% -$1.66M ﹤0.01% 2878
2022
Q1 		$4.83M Sell
257,542
-18,979
-7% -$386K ﹤0.01% 2354
2021
Q4 		$6.64M Buy
276,521
+216,784
+363% +$7.93M 0.01% 2080
2021
Q3 		$2.92M Buy
+59,737
New +$3.48M ﹤0.01% 2648

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's ATOS Position: Q3 2023 in Review

David Shaw sold out of Atossa Therapeutics (ATOS) in Q3 2023, closing a stake of 14,435 shares — an estimated $273K sold.

David Shaw first reported a position in ATOS in Q3 2021 and held it in 8 quarters. The position peaked at $6.64M in Q4 2021. 54 funds tracked by Wall St. Rank hold ATOS as of Q3 2023.

  • David Shaw reported no remaining Atossa Therapeutics position as of Q3 2023 after selling out during the quarter.
  • David Shaw sold 14,435 Atossa Therapeutics shares in Q3 2023, an estimated $273K.
  • David Shaw first reported a position in Atossa Therapeutics in Q3 2021 and held it in 8 quarters.
  • David Shaw's Atossa Therapeutics position peaked at $6.64M in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.